Trexquant Investment LP Increases Stock Holdings in Denali Therapeutics Inc. $DNLI

Key Points

• Trexquant Investment LP increased its holdings in Denali Therapeutics by 86.7%, acquiring an additional 52,568 shares, bringing their total ownership to approximately $1.54 million.
• Denali Therapeutics reported a quarterly EPS of ($0.72), exceeding analysts' expectations, while sell-side analysts predict an average EPS of ($2.71) for the current year.
• Institutional investors collectively own 92.92% of Denali Therapeutics, while insider transactions indicate significant stock sales, including CEO Ryan J. Watts selling over 495,000 shares.

Trexquant Investment LP grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 86.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 113,224 shares of the company's stock after purchasing an additional 52,568 shares during the quarter. Trexquant Investment LP owned approximately 0.08% of Denali Therapeutics worth $1,539,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC boosted its stake in shares of Denali Therapeutics by 339.6% during the first quarter. SG Americas Securities LLC now owns 48,365 shares of the company's stock valued at $658,000 after purchasing an additional 37,362 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Denali Therapeutics by 4.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company's stock worth $1,733,000 after acquiring an additional 3,411 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Denali Therapeutics in the first quarter worth about $254,000. GAMMA Investing LLC lifted its stake in Denali Therapeutics by 253.8% in the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock worth $108,000 after acquiring an additional 5,705 shares during the period. Finally, Millennium Management LLC lifted its stake in Denali Therapeutics by 571.8% in the fourth quarter. Millennium Management LLC now owns 404,224 shares of the company's stock worth $8,238,000 after acquiring an additional 344,056 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan J. Watts sold 495,282 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares in the company, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is owned by company insiders.

Denali Therapeutics Stock Down 4.3%

Shares of DNLI traded down $0.66 during mid-day trading on Wednesday, hitting $14.70. 910,576 shares of the company traded hands, compared to its average volume of 1,475,244. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $2.15 billion, a PE ratio of -5.26 and a beta of 1.23. The business has a 50 day moving average of $14.61 and a 200 day moving average of $14.52.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the company posted ($0.59) EPS. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Morgan Stanley lowered their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a research note on Monday, August 18th. Bank of America lowered their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Denali Therapeutics in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Denali Therapeutics presently has an average rating of "Buy" and a consensus target price of $33.50.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.